HIV and viral protein effects on the blood brain barrier.
Tissue Barriers, 2016 Jan; 4(1):e1143543.
The effects of human immunodeficiency virus infection on the expression of the drug efflux proteins P-glycoprotein and breast cancer resistance protein in a human intestine model.
J Pharm Pharmacol, 2015 Feb; 67(2):178-88
Differential expression of the alternatively-spliced OPRM1 isoform MOR-1K in HIV-infected Subjects.
AIDS, 2014 Jan 2; 28(1):19-30.
Safety, Tolerability and Efficacy of KP-1461 as Monotherapy for 124 Days in Antiretroviral-Experienced, HIV-1-Infected Subjects.
AIDS Research and Human Retroviruses, 2012 Jun 28.
Postpartum Pharmacokinetics of Peramivir in the Treatment of Influenza H1N1: A Case Report.
Obstetrics & Gynecology, 2011 Aug; 118(2 Pt 2):463-7.
Safety, Tolerability, and Pharmacokinetics of KP-1461 in Phase I Clinical Studies: A Single Oral Dose Study in Non-HIV-Infected Adults, and a 14-Day Dose-Escalating Study in Highly Antiretroviral-Experienced HIV-Infected Adults.
J Int Assoc Physicians AIDS Care, 2011 Jul-Aug; 10(4):232-8.
Plasma Bile Acid Concentrations in HIV Infected Subjects Taking Protease Inhibitor Therapy: Possible Implications for Hepatotoxicity.
Pharmacotherapy, 2010 Jan;30(1): 17-24.
Pharmacokinetics of once-daily fosamprenavir 1400 mg plus atazanavir 400 mg without ritonavir in HIV negative subjects.
Pharmacotherapy, 2009 Aug;29(8):937-42.
“One Pill, Once Daily": What clinicians need to know about Atripla®.
Clinical Therapeutics and Risk Management, 2008, 4(2):291-302.
Ritonavir, Saquinavir and Efavirenz, but not Nevirapine, Inhibit Bile Acid Transport in Human and Rat Hepatocytes.
Journal of Pharmacology and Experimental Therapeutics, 2006, 318 (3): 1068-75.
Cytokine Regulation of P-Glycoprotein.
Drug Metabolism Reviews, 2003, 35 (1): 19-33.